Even though PD-1/PD-L1 inhibitors have been known as “anti-tumor miracle drugs”, their application prospects are limited by immune-related adverse events, such as diarrhea, colitis, infections, and infestations.102. The gene discussed is CD274; the disease is neoplasm.